phenyl acetate has been researched along with varespladib methyl in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 15 (83.33) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Karakas, M; Koenig, W | 1 |
| Rosenson, RS | 1 |
| Fraser, H; Hislop, C; Rosenson, RS; Trias, J | 1 |
| Elliott, M; Hislop, C; Rosenson, RS; Stasiv, Y | 1 |
| Arsenault, BJ; Boekholdt, SM; Kastelein, JJ | 1 |
| Fraser, H; Goulder, MA; Hislop, C; Rosenson, RS | 1 |
| Bash, D; Cavender, MA; Hislop, C; Kastelein, JJ; Nicholls, SJ; Rosenson, RS; Schwartz, G; Waters, DD | 1 |
| Hurt-Camejo, E; Rosenson, RS | 1 |
| Guo, Y; Li, B; Li, W; Wu, R; Xu, X | 1 |
| Bickler, P; Lewin, M; Merkel, J; Samuel, S | 1 |
| Bickler, PE; Bryan-Quirós, W; Bulfone, TC; Gutiérrez, JM; Herrera, M; Lewin, MR; Lomonte, B; Samuel, SP; Williams, DJ | 1 |
| Bryan-Quirós, W; Fernández, J; Gutiérrez, JM; Lewin, MR; Lomonte, B | 1 |
| Bickler, PE; Bulfone, TC; Gilliam, J; Gilliam, LL; Gutiérrez, JM; Lewin, MR; Samuel, SP | 1 |
| Bittenbinder, MA; Dobson, JS; Fry, BG; Naude, A; Op den Brouw, B; Vonk, FJ; Youngman, NJ; Zdenek, CN | 1 |
| Armando, A; Dennis, EA; Mouchlis, VD | 1 |
| Gutiérrez, JM; Lewin, MR; Lomonte, B; Williams, DJ | 1 |
| Fortes-Dias, CL; Garrido Cavalcante, WL; Gonçalves de Abreu, TA; Maciel, FV; Ortolani, PL; Ramos Pinto, ÊK; Valério Souza, NM | 1 |
4 review(s) available for phenyl acetate and varespladib methyl
| Article | Year |
|---|---|
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Biomarkers; Controlled Clinical Trials as Topic; Disease Models, Animal; Dosage Forms; Humans; Indoles; Keto Acids; Mice; Mice, Transgenic; Molecular Targeted Therapy; Oximes; Phospholipases A2, Secretory; Risk Factors | 2010 |
Varespladib methyl in cardiovascular disease.
Topics: Acetates; Animals; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Indoles; Inflammation; Keto Acids; Male; Phospholipases A2, Secretory | 2010 |
Varespladib.
Topics: Acetates; Acute Coronary Syndrome; Animals; Clinical Trials as Topic; Humans; Indoles; Keto Acids | 2011 |
Phospholipase A2 enzymes and the risk of atherosclerosis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Enzyme Inhibitors; Guinea Pigs; Humans; Indoles; Keto Acids; Mice; Mutation, Missense; Myocardial Ischemia; Myocytes, Cardiac; Oximes; Phospholipases A2, Secretory; Polymorphism, Genetic; Risk Factors | 2012 |
3 trial(s) available for phenyl acetate and varespladib methyl
| Article | Year |
|---|---|
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
Topics: Acetates; Aged; Apolipoproteins B; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Keto Acids; Male; Phospholipases A2, Secretory; Triglycerides | 2011 |
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
Topics: Acetates; Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Keto Acids; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Topics: Acetates; Acute Coronary Syndrome; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Keto Acids; Phospholipases A2, Secretory; Pyrroles | 2012 |
11 other study(ies) available for phenyl acetate and varespladib methyl
| Article | Year |
|---|---|
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
Topics: Acetates; Animals; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Patents as Topic; Phospholipases A2, Secretory; Prodrugs | 2009 |
Varespladib: targeting the inflammatory face of atherosclerosis.
Topics: Acetates; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Keto Acids; Male; Phospholipases A2, Secretory | 2011 |
sPLA2-IIA Augments Oxidized LDL-Induced MCP-1 Expression in Vitro Through Activation of Akt.
Topics: Acetates; Cell Line; Chemokine CCL2; Chromones; Enzyme-Linked Immunosorbent Assay; Gene Expression; Genes, Reporter; Group II Phospholipases A2; HEK293 Cells; Humans; Indoles; Keto Acids; Lipoproteins, LDL; Morpholines; Myocytes, Smooth Muscle; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Messenger | 2015 |
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.
Topics: Acetates; Animals; Antidotes; Disease Models, Animal; Dose-Response Relationship, Drug; Elapid Venoms; Indoles; Keto Acids; Mice; Phospholipase A2 Inhibitors; Phospholipases A2; Prodrugs; Rats, Sprague-Dawley; Reptilian Proteins; Snake Bites; Time Factors; Viper Venoms | 2016 |
Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.
Topics: Acetates; Administration, Oral; Animals; Antivenins; Elapid Venoms; Elapidae; Female; Indoles; Keto Acids; Male; Mice; Neurotoxins; Phospholipase A2 Inhibitors | 2018 |
Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A
Topics: Acetates; Animals; Cells, Cultured; Crotalid Venoms; Crotoxin; Elapid Venoms; Female; Group I Phospholipases A2; Group II Phospholipases A2; Indoles; Keto Acids; Male; Mice; Muscle Fibers, Skeletal; Muscles; Reptilian Proteins | 2019 |
Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of
Topics: Acetates; Administration, Intravenous; Administration, Oral; Animals; Antivenins; Blood Coagulation; Coral Snakes; Elapid Venoms; Female; Indoles; Keto Acids; Neuroprotective Agents; Neurotoxicity Syndromes; Phospholipase A2 Inhibitors; Snake Bites; Swine | 2018 |
Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib).
Topics: Acetates; Animals; Anticoagulants; Antivenins; Blood Coagulation; Elapid Venoms; Elapidae; Factor Va; Factor Xa; Fibrinogen; Humans; Indoles; Keto Acids; Phospholipase A2 Inhibitors; Snake Bites | 2018 |
Substrate-Specific Inhibition Constants for Phospholipase A
Topics: Acetates; Catalytic Domain; Enzyme Assays; Group VI Phospholipases A2; Humans; Indoles; Keto Acids; Lipidomics; Membranes, Artificial; Micelles; Molecular Dynamics Simulation; Phospholipase A2 Inhibitors; Phospholipids; Pyrrolidines | 2019 |
Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.
Topics: Acetates; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Indoles; Keto Acids; Lethal Dose 50; Mice; Neurotoxicity Syndromes; Phospholipase A2 Inhibitors; Phospholipases A2; Snake Bites; Snake Venoms; Survival Analysis; Time Factors | 2020 |
Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations.
Topics: Acetates; Animals; Crotalid Venoms; Crotoxin; Indoles; Keto Acids; Mice; Myotoxicity | 2021 |